Xencor Inc (XNCR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$34.05-2.80%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · XNCR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -8.9% |
| Our one-year growth estimate | diamond | -35.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 26.5 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
XNCR — earnings miss
Dated 2026-05-06
Results of Operations and Financial Condition” of this Current Report on Form 8-K and in Exhibit 99.1 attached hereto is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly s…
Why it matters: Xencor is focusing on this study after early XmAb541 activity. Reaching the target dose range would test the combination plan. Delays or safety limits could weaken it.
Watch forThe Phase 1 combination study reaches its target dose range in 2027. No safety issue stops dose escalation.
Also watch forThe study does not reach its target dose range in 2027, or a safety issue stops dose escalation.
Why it matters: A start in 2027 would mark a move from Phase 1 testing toward a study meant to support registration. A delay would push that step back.
Supportive ifXencor starts enrollment in the XmAb819 ccRCC study, which can support registration, during 2027.
Worry ifXencor delays the study beyond 2027, or reports that it cannot start as planned.
Why it matters: XmAb412 is Xencor's first drug built with its XenLock platform. Human data will test its safety and dosing plans after preclinical work.
Watch forXencor reports initial Phase 1 data in 1H27. No serious safety issue stops dose escalation.
Also watch forXencor reports a serious safety issue, stops dose increases, or delays the first data past 1H27.
Why it matters: The interim review and week-12 remission result are key tests of XmAb942 in ulcerative colitis. They can show whether the trial is on track and whether treatment helps patients reach remission.
Watch forXencor reports the blinded interim review around year-end 2026. It then reports week-12 remission data in 2H27.
Also watch forThe interim review or week-12 result slips beyond its stated window, or week-12 remission fails to beat placebo.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$237 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $562 loss on $10,000 · 5.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,261 loss on $10,000 · 42.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.